ABL Bio and I-Mab Biopharma ink bispecific antibody deal
ABL Bio and I-Mab Biopharma have partnered to develop bispecific antibodies for immunotherapy.
Archives for August 14, 2018
Regulatory eyes on Regeneron: US FDA issues CRL for Eylea
The US Food and Drug Administration has rejected Regeneron’s eye candidate, Eylea, but the biotech says it expects a final regulatory decision within two months.
Motion to dismiss Inflectra case denied, but J&J insists ‘Pfizer’s lawsuit is without merit’
A US district court has denied Johnson & Johnson’s motion to dismiss Pfizer’s Inflectra lawsuit, a case claiming anticompetitive practices blocked US uptake of the Remicade biosimilar.